Bladder Instillation of Melatonin for Radiation Cystitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for radiation cystitis are largely symptomatic and do not address the root cause of the pathology, which is the damage to healthy cells caused by the generation of intracellular free radicals as a direct and immediate effect of irradiation, and the persistence of an inflammatory and fibrotic response.
Innovation Solution
Pharmaceutical compositions comprising melatonin and/or its antioxidant metabolites, derivatives, or analogues, optionally with vitamin E, coenzyme Q10, alpha-lipoic acid, and vitamin C, are directly administered to the bladder epithelium to prevent and treat radiation cystitis by scavenging free radicals and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If systemic treatments are used for radiation cystitis, then the treatment can be administered easily, but the effectiveness is reduced due to poor bioavailability and first-pass metabolism in the liver
Solution Approach 1:
The patent uses the bladder itself as an intermediary reservoir to deliver melatonin directly to the target tissue. By instilling melatonin into the bladder, the drug is positioned in direct contact with the bladder epithelium, bypassing the liver's first-pass metabolism and achieving high local concentrations where needed.
Solution Approach 2:
The patent segments the administration route by separating systemic distribution from local target delivery. Instead of relying on systemic circulation, the treatment is delivered locally through bladder instillation, creating a direct pathway from administration site to target tissue.
2Quantity of substance
If high doses of melatonin are administered systemically to ensure adequate tissue levels, then the target tissue receives sufficient drug, but the liver undergoes extensive first-pass metabolism reducing overall availability
Solution Approach 1:
The patent extracts the drug delivery from the systemic circulation pathway and places it directly at the target site. By removing melatonin from general circulation and delivering it directly to the bladder tissue through instillation, the liver's metabolic pathway is completely bypassed, eliminating first-pass loss.
Solution Approach 2:
The patent applies melatonin to the bladder epithelium before radiation-induced damage occurs or at the onset of cystitis, ensuring the tissue is pre-saturated with protective agent. This preliminary local application ensures adequate tissue levels without requiring high systemic doses that would be metabolized by the liver.
3Device complexity
If current symptomatic treatments are used for radiation cystitis, then the treatment approach is simple, but the root cause of pathology involving free radicals and inflammation is not addressed
Solution Approach 1:
The patent changes the fundamental parameter of treatment mechanism from symptomatic management to病因治疗 (etiological treatment). By using melatonin's antioxidant properties to neutralize free radicals and reduce inflammation at the source, the treatment addresses the root pathological process rather than merely managing symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The direct administration of melatonin and associated antioxidants to the bladder epithelium effectively prevents and treats radiation cystitis by mitigating the intracellular damage caused by ionizing radiation, providing a more targeted and effective solution than systemic treatments.
Implementation Method 1
Radiation interacts with intracellular water and produces free radicals to an extent that exceeds the cells' intrinsic scavenging capabilities... Pharmaceutical compositions comprising melatonin and/or an antioxidant metabolite, derivative or analogue thereof... to prevent and treat radiation cystitis by scavenging free radicals
Data Source
AI summary
Compositions comprising melatonin and/or derivatives thereof are provided for topical administration to the epithelium of the urinary bladder by instillation into the bladder to protect against or treat bladder injury due to irradiation and/or cytotoxic agents.